Laurus Labs Ltd (LAURUSLABS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Laurus Labs Ltd (LAURUSLABS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8140
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Laurus Labs Ltd (Laurus Labs) is a drug development company that manufactures active pharmaceutical ingredients. The company develops products through its business divisions such as laurus generics, ingredients and synthesis. It offers active pharmaceutical ingredients and intermediates for anti-retroviral and Hepatitis C. Laurus Labs also provides active pharmaceutical ingredients for oncology and other therapeutic areas. The company manufactures ingredients for use in nutraceutical, dietary supplements and cosmeceutical products. It also offers drug substance, analytical development and product development services. The company operates research and development, and drug substance manufacturing facilities in Hyderabad and Visakhapatnam. Laurus Labs is headquartered in Hyderabad, Telangana, India.

Laurus Labs Ltd (LAURUSLABS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Laurus Labs Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Private Equity 10
Warburg Pincus Acquires 32.29% Stake in Laurus Labs for USD90 Million 10
Fidelity Growth Partners India Invests US$40 Million In Aptuit Laurus 12
Licensing Agreements 13
Laurus Labs Enters into Licensing Agreement with Medicines Patent Pool 13
MPP, Bristol-Myers Squibb and Laurus Labs Enter into Licensing Agreement For Daclatasvir 14
Laurus Labs Enters into Licensing Agreement with MPP and ViiV Healthcare For Dolutegravir 15
Laurus Labs Amends Licensing Agreement with MPP and Gilead Sciences 16
Equity Offering 17
Laurus Labs Raises USD194 Million in IPO 17
Acquisition 18
Laurus Labs Acquires 27% Stake in Sriam Labs for USD1.2 Million 18
Laurus Labs Ltd – Key Competitors 19
Laurus Labs Ltd – Key Employees 20
Laurus Labs Ltd – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Joint Venture 22
Recent Developments 23
Financial Announcements 23
Nov 09, 2017: Laurus Labs Records Healthy Performance, PAT Grows at 19% in H1 FY I8 23
May 18, 2017: Laurus Labs Reports Revenue Of INR19.3 Billion In Fiscal 2018 25
Feb 09, 2017: Laurus Labs Demonstrates Strong Q3 Growth in the First Quarterly Results After Successful IPO 26
Corporate Communications 27
Mar 08, 2018: Laurus Labs: Resignation of Executive Director 27
Mar 08, 2018: Laurus Labs Appoints Dr. Venkata Lakshmana Rao Chunduru as Executive Director 28
Mar 28, 2017: Laurus Labs Announces Resignation of Director 29
Jan 02, 2017: Laurus Labs: Resignation of Director 30
Legal and Regulatory 31
Mar 01, 2018: Laurus Labs Completes USFDA Inspection Of Unit 2 With No Observations- Zero 483 31
Nov 14, 2017: laurus labs recieves the EIR for its unit 1 & 3 32
Sep 15, 2017: Laurus Labs Recivces the EIR from UFDA, and also Successfully Completes of the German Regulatory Authority for Unit-2 and WHO inspections for Unit-3 API Facilities 33
Aug 18, 2017: Laurus Labs Announces Successful Completion of U.S. FDA Inspection for Unit-1 and Unit-3 API Facilities 34
May 19, 2017: Laurus Labs Announces Successful Completion of U.S. FDA Inspection 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Laurus Labs Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Laurus Labs Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Warburg Pincus Acquires 32.29% Stake in Laurus Labs for USD90 Million 10
Fidelity Growth Partners India Invests US$40 Million In Aptuit Laurus 12
Laurus Labs Enters into Licensing Agreement with Medicines Patent Pool 13
MPP, Bristol-Myers Squibb and Laurus Labs Enter into Licensing Agreement For Daclatasvir 14
Laurus Labs Enters into Licensing Agreement with MPP and ViiV Healthcare For Dolutegravir 15
Laurus Labs Amends Licensing Agreement with MPP and Gilead Sciences 16
Laurus Labs Raises USD194 Million in IPO 17
Laurus Labs Acquires 27% Stake in Sriam Labs for USD1.2 Million 18
Laurus Labs Ltd, Key Competitors 19
Laurus Labs Ltd, Key Employees 20
Laurus Labs Ltd, Other Locations 21
Laurus Labs Ltd, Subsidiaries 21
Laurus Labs Ltd, Joint Venture 22

List of Figures
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Laurus Labs Ltd (LAURUSLABS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Telekom Malaysia Bhd (TM):企業の財務・戦略的SWOT分析
    Telekom Malaysia Bhd (TM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Engineers India Ltd (ENGINERSIN):企業の財務・戦略的SWOT分析
    Engineers India Ltd (ENGINERSIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Greencore Group Plc:企業のM&A・事業提携・投資動向
    Greencore Group Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Greencore Group Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Tanfield Group PLC (TAN):企業の財務・戦略的SWOT分析
    Summary Tanfield Group plc (Tanfield Group) is an investment company that offers electrical investments. The company designs and produces electric commercial vehicles for short haul urban fleets. It also produces zero-emission vehicles that deliver better performance to traditional diesel trucks. Ta …
  • ArcDia International Oy Ltd:医療機器:M&Aディール及び事業提携情報
    Summary ArcDia International Oy Ltd (ArcDia International) is a healthcare service provider that offers vitro diagnostic services and develops products for the rapid testing of infectious diseases. The company's products include maripoc test system, an automated system for rapid multianalyte identif …
  • Occidental Petroleum Corporation (OXY)-エネルギー分野:企業M&A・提携分析
    Summary Occidental Petroleum Corporation (Occidental) is an oil and gas exploration and production company with integrated assets. The company is active in upstream exploration and production; midstream and marketing; and chemicals business. The oil and gas business explores for, develops and produc …
  • Tenaska Inc:企業の発電所・SWOT分析2018
    Tenaska Inc - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (execut …
  • Collegium Pharmaceutical Inc (COLL):製薬・医療:M&Aディール及び事業提携情報
    Summary Collegium Pharmaceutical Inc (Collegium) is a specialty pharmaceutical company that focuses on the development and commercialization of innovative products for treating patients suffering from pain. The company develops products based on its DETERx platform technology. DETERx offers extended …
  • Diagnostics For All Inc:企業の製品パイプライン分析
    Summary Diagnostics For All Inc (DFA) is a drug development company that develops and commercializes of new technology and practical diagnostic devices for diagnostic companies. The company uses patterned paper technology to create electrochemical clinical chemistry assays, immunoassays, assays, and …
  • Lowe’s Companies, Inc.:戦略・SWOT・企業財務分析
    Lowe's Companies, Inc. - Strategy, SWOT and Corporate Finance Report Summary Lowe's Companies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Kiniksa Pharmaceuticals Ltd (KNSA):製薬・医療:M&Aディール及び事業提携情報
    Summary Kiniksa Pharmaceuticals Ltd (Kiniksa Pharmaceuticals) is a clinical-stage biopharmaceutical company focused on discovery, acquisition, development and commercialization of therapeutic medicines for the treatment of auto inflammatory and autoimmune diseases. Its pipeline product portfolio inc …
  • Eyevensys SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary Eyevensys SAS (Eyevensys) is a clinical stage biotechnology company developing non-viral gene therapies for ophthalmic diseases. Its lead product, EYS-606, is a soluble TNFa receptor plasmid associated with the ETIS device to treat non-infectious intermediate and posterior uveitis(NIU); EYS- …
  • Sui Northern Gas Pipelines Ltd (SNGP):企業の財務・戦略的SWOT分析
    Sui Northern Gas Pipelines Ltd (SNGP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Norwegian Energy Company ASA (NOR):石油・ガス:M&Aディール及び事業提携情報
    Summary Norwegian Energy Company ASA (Noreco) is an oil and gas company that offers exploration and development services. The company explores, produces and develops oil, gas, and natural gas liquids deposit properties. It operates through ongoing and planned exploration wells such as PL616 Haribo a …
  • Sabine Oil & Gas Corporation-石油・ガス分野:企業M&A・提携分析
    Summary Sabine Oil & Gas Corporation (Sabine Oil), formerly known as Forest Oil Corporation is an independent oil and gas company. The company focuses on acquisition, exploitation, development and exploration of oil and natural gas properties onshore in the US. Its core areas of operations include E …
  • Guess, Inc.:企業の戦略・SWOT・財務情報
    Guess, Inc. - Strategy, SWOT and Corporate Finance Report Summary Guess, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • TechnipFMC Plc (FTI):企業の財務・戦略的SWOT分析
    TechnipFMC Plc (FTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Television Francaise 1 SA:企業の戦略・SWOT・財務分析
    Television Francaise 1 SA - Strategy, SWOT and Corporate Finance Report Summary Television Francaise 1 SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Stiefel Laboratories Inc-製薬・医療分野:企業M&A・提携分析
    Summary Stiefel Laboratories Inc (Stiefel Laboratories), a subsidiary of GlaxoSmithKline Plc is a healthcare products provider that develops products for sun care, dry skin and clear skin. The company also offers research and development, manufacture, marketing and distribution of prescription medic …
  • Taisei Corporation:企業の戦略・SWOT・財務分析
    Taisei Corporation - Strategy, SWOT and Corporate Finance Report Summary Taisei Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆